Alkem Laboratories Incorporates 51%-Owned Joint Venture Subsidiary in Saudi Arabia
Alkem Laboratories Ltd 路 Others (Uncategorized) 路 09 Nov 2026, 12:12 am
Alkem Laboratories Incorporates 51%-Owned Joint Venture Subsidiary in Saudi Arabia Alkem Laboratories incorporated a joint venture subsidiary, Alkem Pharma Company LLC, in Saudi Arabia on 8th Nov'26 to expand its pharmaceutical and nutraceutical business in the region. Alkem subscribed to a 51% stake comprising 38,250 shares at 100 SAR per share for a total cash consideration of SAR 3.825 mn. The subsidiary has a total capital of SAR 7.5 mn and will engage in manufacturing, importing, marketing, and distributing pharmaceutical and nutraceutical products across Saudi Arabia. The transaction is non-related-party.
Original exchange filing (PDF)
More announcements from Alkem Laboratories Ltd
- With reference to relevant provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of the '' Q2 and H1FY27 Earnings Conference Call'' .... 路 13 Nov 2026
- We wish to inform you that the Company has appointed Mr. Gopal Kothari as the CFO and KMP of the Company wef 2nd Dec, 2026. 路 12 Nov 2026
- Pl find enclosed press release and analyst presentation on Q2 and H1FY27 earnings and business updates of the Company 路 12 Nov 2026
- Pl find enclosed unaudited financial results along with Limited Review Report of the Company for quarter and half year ended 30th Sept, 2026. 路 12 Nov 2026
- Alkem Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 12 Nov 2026
- Please find enclosed herewith the outcome of Board meeting dated 12th Nov, 2026. The meeting of the Board of Directors of the Company commenced at 11.30 am and concluded at 13.40. 路 12 Nov 2026
- With reference to your email regarding the captioned corporate announcement submitted by the Company on 03rd November, 2026 under Regulation 30 of the SEBI (Listing Obligations and Disclosure .... 路 05 Nov 2026
- Please find attached herewith intimation for Analyst / Investor Meet. 路 12 Nov 2026
